The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve.
Michael Greve, founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures, announced today that he will make available an additional €300 million to be invested in rejuvenation biotech.
Longevity.Technology: €300m ($360m) is a sizeable amount to plough into rejuvenation biotech. The funds, which will be deployed via Kizoo, will be used to create and support more start-ups in the rejuvenation space, allowing Kizoo to maintain a strong commitment to its key start-ups during follow-up rounds. Crucially, it will allow therapies to advance from clinical development to public availability.
We were delighted to talk to Michael Greve ahead of today’s announcement to find out more…
With this €300 million commitment, Greve and Kizoo double down on their mission to accelerate the advent of rejuvenation biotechnology by doing lighthouse investments in entirely new, repair-based approaches that treat the root causes of aging and thus overcome age-related diseases. Through the creation of successful companies, they seek to inspire scientists, investors, and the general public by demonstrating that human rejuvenation is not science fiction anymore and that the resulting therapies are affordable and uncomplicated.
Technologies pioneered by Kizoo’s start-ups include removal of arterial plaque, decalcification of aged tissue, breaking of protein-glucose cross-links, and delivery of new mitochondria to aged cells – all aiming to prevent and repair common age-related conditions such as myocardial infarction, stroke, high blood pressure, tissue stiffening, skin aging and loss of muscle function.
Michael Greve says: “I am really grateful that we can use the funds we have created with our highly successful technology ventures to contribute to the quest to get aging under full medical control and to make age-related diseases a thing of the past. For me, it is a worthy cause that is exciting in a technological, commercial, and above all, a humanitarian way.”
Greve expects that the new funds, in combination with the strong, multi-round commitment of Kizoo to its key start-ups, should trigger co-investments of up to 3-4 times the initial amount, resulting in a significant acceleration of the development and public availability of the therapies.
